1921
Volume 85, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

We report an unusual case of visceral leishmaniasis occurring in a patient from Sichuan China. The patient presented with a remitting fever, anemia, and pancytopenia. The case was confirmed as visceral leishmaniasis by microscopical detection of the species amastigote in bone marrow aspirate. The patient was treated with 10 mg/kg/day of sodium stibogluconate for 5 days, with no therapeutic response. As a result, the patient was treated with liposomal amphotericin B (LAB) at 10 mg/day as an initial dosage. After treatment with an increasing drug dosage for 7 days, acute renal injury was evident as indicated by increased serum creatinine and urea nitrogen. LAB administration was discontinued until serum creatinine and serum urea nitrogen regressed on Day 15. Two maintenance treatments of 100 mg/day LAB were given on Days 19 and 26 (total 870 mg, 14.5 mg/kg). Bone marrow aspirate and clinical examination suggested total remission.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2011.11-0449
2011-12-01
2017-11-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/85/6/1035.html?itemId=/content/journals/10.4269/ajtmh.2011.11-0449&mimeType=html&fmt=ahah

References

  1. Zhang LP, Zhang FN, , 2010. Epidemiological and clinical analysis of 166 kala-azar cases. Parasites Infect Dis 18: 181186.
  2. Killick-Kendrick R, , 2010. Education is key to controlling visceral leishmaniasis. Bull World Health Organ 88: 1112.[Crossref]
  3. Mondal S, Bhattacharya P, Ali N, , 2010. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther 8: 919944.[Crossref]
  4. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F, , 2011. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomized controlled trial. Lancet 377: 477486.[Crossref]
  5. Kang X, Liu Y, Liu K, Lu X, , 2009. Human leishmaniasis: a retrospective clinical analysis of 86 patients. Chin J Infect Chemother 9: 241243.
  6. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J, , 2006. Liposomal amphotericin B for the treatment visceral leishmaniasis. Clin Infect Dis 43: 917924.[Crossref]
  7. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, , 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504512.[Crossref]
  8. Thakur CP, , 2001. A single high dose treatment of kala-azar with AmBisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 17: 6770.[Crossref]
  9. Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, Rabi Das VN, Gupta J, Kumar N, Mitra G, Saint-Sauveur JF, Seena S, Balasegaram M, Parreño F, Pandey K, , 2010. Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg 83: 357364.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2011.11-0449
Loading
/content/journals/10.4269/ajtmh.2011.11-0449
Loading

Data & Media loading...

  • Received : 12 Jul 2011
  • Accepted : 21 Sep 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error